Truist Securities Downgrades Marinus Pharmaceuticals (MRNS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Marinus Pharmaceuticals (MRNS) PT Lowered to $0.50 at Baird
October 24, 2024 1:59 PM EDTBaird analyst Brian Skorney lowered the price target on Marinus Pharmaceuticals (NASDAQ: MRNS) to $0.50 (from $2.00) while maintaining a Neutral rating.
The analyst comments "Negative on clinical and strategic update. The company announced this morning that Phase 3 study of ganaxolone in... More
